GLP1R and Parkinson disease: Another study analyzing the impact on Parkinson's disease in cellular and animal models discovered that the GLP-1 receptors have neuroprotective effects on the dopamine pathways as the drug is able to increase phosphorylated adenosine monophosphate-activated protein kinase (p-AMPK) expressions and also reduce the nuclear factor-kappa B (NF-kB) protein levels [38].